Syndax PharmaceuticalsSNDX
Recorded

Syndax Pharmaceuticals 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration25 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul JengAnalyst

Welcome to this next session. My name is Paul Jeng. I am a biotech analyst. Company is Syndax, and I am with Nick Botwood, CMO.

Paul JengAnalyst

Good with you. Great. Maybe a good place to start is for those that might be newer to the story, could you provide a quick overview of Syndax and your two launch medicines, Revuforj and Niktimvo, as well as the main value drivers for the next few years?

Nick BotwoodCMO

Yeah. Thanks so much. Sure. Syndax is a fully integrated commercial and R&D company. We are now commercializing two agents, Niktimvo and Revuforj. Revuforj is for acute AML and ALL, specifically two subtypes, KMT2A acute leukemia and NPM1 mutant leukemia. We are indicated for both adults and pediatrics in those populations, and we were the first to pioneer a new class of medicines called the menin class. We are now the leader in that category and continuing on our leadership as we have launched that product, as we are about in our second year of launch now. We recently had our quarterly results. Product is continuing to grow very nicely, and we are continuing with our dominant position across all the segments.

Nick BotwoodCMO

That product, we are continuing also to advance into additional trials and move it into the frontline setting, which is a multi-billion dollar category, and we are very excited about what comes next for Revuforj. Then I will say for Niktimvo, it is very similar in the sense that we launched the product in 2025. Now we are in our second year. Product is doing very, very well, growing quarter-to-quarter. Like Revuforj, we are growing new patient starts. We are also growing revenue. The last quarter showed growth for Niktimvo of revenue growth of 12%. Revuforj grew 11%. Then, of course, we are now advancing both products to frontline indications. Niktimvo will have some data in the first quarter of next year, really looking at newly diagnosed populations, and then a pivotal trial in early 2028. Both are expanding franchises. Both have a really nice leadership position for us.

Nick BotwoodCMO

We continue on building the rest of the company as well, so it is not just commercial products, which are exciting, but also we have a pipeline now which we have started to talk about. One is a mutant selective EGFR inhibitor. It is an allosteric, the first of its kind to go into the clinic. We will file that IND at the end of this year and then start clinical trials next year. So exciting new wave of science for us as we pioneer a new mechanism. Then, of course, there is a next generation menin inhibitor for myelofibrosis, which we presented data at ASH last year, and then we published some data this year indicating the mechanism should be active in that disease as well. So that is a whole new area of science for us in myelofibrosis, which we are excited about.

Nick BotwoodCMO

We should have some data with Revuforj in that category, and then also follow on with the IND in 2027. So lots of important milestones. I know you asked and where we are going. I think we could see that we will continue to build our position with Revuforj and Niktimvo, and so that is commercial performance, but it is also clinical performance, as well as the new pipeline, which is emerging quickly.

Paul JengAnalyst

Okay, fantastic. So maybe starting with the commercial front, and as you mentioned, you just had earnings for Revuforj, roughly $61 million. So I guess what are the key drivers at this point in the launch curve, and two years in, is it more new patient starts? Is it longer time on treatment, or are there some other factors at play?

Nick BotwoodCMO

Well, it is certainly both, right? I think we, as I mentioned, we have sort of the dominant position in new patient starts. If you look across the entire category of age, you can see that we have new patients entering every month and growing every month. So we feel quite good about new patient starts. If you look at from a revenue perspective, 80% plus of the revenue for the category in relapsed refractory disease. So that just tells you how vast the opportunity is for us and how we will continue to build on that leadership position.

Nick BotwoodCMO

But when it comes to how the business grows, it is not only new patient starts, it is also recurring revenue, it is also patients staying on therapy for longer, driven by the fact that we treat patients earlier and earlier in the relapse refractory setting, which gets them to a higher rate of response. Then you can take them to transplant in higher numbers, which we are seeing quarter to quarter as that builds, and then bringing them back and physicians putting them on for maintenance, which adds a whole another dimension of growth to how Revuforj will continue.

Nick BotwoodCMO

So you have this new patient start, of course, is important, but bringing patients back for maintenance, which is up this quarter from last quarter, not only for KMT2A, which is now at about 60% of the patients coming back for maintenance that have gone to transplant, but you are seeing NPM1 patients increasingly go to transplant and also come back for maintenance. That is 50% this quarter. So I think that aspect of our business is an enduring piece and a differentiator for us as we get into even earlier lines where we are going to see hopefully patients staying on therapy for months, if not years.

Paul JengAnalyst

Okay. Yeah, I know the sort of getting to transplant and then maintenance dynamic is a big part of the Revuforj story. So I am just curious about how you think about where the trajectory can land in terms of like how many patients could you actually be getting into transplant for the respective KMT2A and NPM1 settings, and then sort of how many of them could you get onto maintenance as sort of a peak opportunity?

Nick BotwoodCMO

I have to say it's very encouraging. I think what we've seen in this and what we've been able to do with Revuforj, and physicians were very eager when they first saw the data with KMT2A to get these patients through transplants. The only chance you have for an enduring cure for a patient with acute AML, and the ability for Revuforj to do that is unique. Getting them to transplant now, KMT2A at about 50% of the patients getting to transplant and about 60% coming back. I would expect that we could increase the number of patients going to transplant, maybe get to 60% for KMT2A, maybe get to 70%-80% of the patients coming back for maintenance.

Nick BotwoodCMO

What's the big surprise this quarter is that we've looked back at the data, and we're starting to see this phenomenon where even NPM1 patients who are historically a little bit older, less able to necessarily have a transplant, we're actually seeing them go to transplant. So now, this quarter, we saw about 40% of the patients going to transplant and about 50% of those coming back for maintenance. Excellent sign that physicians are actually really pushing this. They really want to get patients onto transplant and then back to maintenance. So that could probably go for NPM1. I would expect we would increase the transplant rate a bit more, and maybe a bit more on the patients returning, so maybe 60%, 70% of the patients returning that are NPM1 for maintenance.

Nick BotwoodCMO

Again, all very positive forward indicators of where the business is going and what Revuforj can specifically do as a leader in the class.

Paul JengAnalyst

Okay. How is that all netting out to your current view on the treatment duration for patients who are either transplanted versus not transplanted?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day